#39;Neurology in Crisis #39;: Drs. Orly Avitzur and Neil Busis Discuss Practice Changes
What should neurologists do to mitigate changes in practice? Neurology Today Associate Editor Orly Avitzur, MD, a neurologist in private practice in Tarrytow...
By: Neurology Today
Original post:
'Neurology in Crisis': Drs. Orly Avitzur and Neil Busis Discuss Practice Changes - Video
New Diagnostic Blood Assay and a Novel Treatment for Inclusion Body Myositis
Two new developments reported at the 2013 American Neurological Association annual meeting have neuromuscular specialists excited for the first time in a whi...
By: Neurology Today
Read the original:
New Diagnostic Blood Assay and a Novel Treatment for Inclusion Body Myositis - Video
CING-CSMM Herb Garden
We are sure you know the benefits of living in a green environment. This is not always possible however especially in urban city centre locations. At the Cyp...
By: Cyprus Institute of Neurology and Genetics
Read more:
CING-CSMM Herb Garden - Video
Should neurologists be lowering blood pressure acutely in intracranial hemorrhage?
Rapid, intensive lowering of intracerebral blood pressure (BP) did not appear to reduce death or severe disability in patients with intracerebral hemorrhage,...
By: Neurology Today
Read more here:
Should neurologists be lowering blood pressure acutely in intracranial hemorrhage? - Video
Neurology Now Editor-in-Chief Dr. Robin Brey at the 2013 Brain Health Fair.
Neurology Now Editor-in-Chief Dr. Robin Brey discusses highlights of the American Brain Foundation #39;s 2013 Brain Health Fair.
By: Neurology Now Magazine
Original post:
Neurology Now Editor-in-Chief Dr. Robin Brey at the 2013 Brain Health Fair. - Video
Neurology Now Editor-in-Chief Dr. Robin Brey at the 2013 AAN Annual Meeting
Neurology Now Editor-in-Chief Dr. Robin Brey discusses research from the 2013 American Academy of Neurology Annual Meeting.
By: Neurology Now Magazine
See the original post here:
Neurology Now Editor-in-Chief Dr. Robin Brey at the 2013 AAN Annual Meeting - Video
Hope Restored Functional Neurology Serves Humanity
"Hope Restored: Functional Neurology Serves Humanity" is a Short Subject Documentary that tells the story of how a new form of modern medical practice is cha...
By: Dr. Mark Saracino, Board Certified Chiropractic Neurologist
Read more:
Hope Restored Functional Neurology Serves Humanity - Video
ABC News Nightline Video Chiropractic Neurology
ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo?
By: Mark Saracino
Read more:
ABC News Nightline Video Chiropractic Neurology - Video
What Is Neurology #39;s Stake in the Quality Measures Movement?
As the health care quality movement gains steam, neurologists are jumping aboard with a wide range of improvement initiatives on everything from the development of programs to reduce avoidable...
By: Neurology Today
View post:
What Is Neurology's Stake in the Quality Measures Movement? - Video
How can neurologists incorporate shared decision-making with their patients?
A survey, reported in JAMA Internal Medicine, reported that primary care physicians are not consistently consulting with patients in discussions and decision...
By: Neurology Today
Read the original post:
How can neurologists incorporate shared decision-making with their patients? - Video
What is the AAN Doing to Advocate for Neurology?
In a video interview with Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Orly Avitzur, MD, former AAN President Dr. Sigsbee discusses the AAN priorities for policy...
By: Neurology Today
The rest is here:
What is the AAN Doing to Advocate for Neurology? - Video
ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo?
ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo?
By: Mark Saracino, Board Certified Chiropractic Neurologist
Go here to read the rest:
ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo? - Video
Related video above: Researchers Developing Most Powerful MRI Hope to Help Detect Illnesses Like Alzheimers Disease SoonerAuthorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's, according to a statement from China's drug safety agency. The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn should any safety issues arise.In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed suppresses certain bacteria contained in the gut which can cause neural degeneration and inflammation of the brain, leading to Alzheimer's.This mechanism was confirmed during a clinical trial carried out by Green Valley, a Shanghai-based pharmaceutical company that will be bringing the new drug to market.Conducted on 818 patients, the trial found that Oligomannate -- which is derived from brown algae -- can statistically improve cognitive function among people with Alzheimer's in as little as four weeks, according to a statement from Green Valley."These results advance our understanding of the mechanisms that play a role in Alzheimer's disease and imply that the gut microbiome is a valid target for the development of therapies," neurologist Philip Scheltens, who advises Green Valley and heads the Alzheimer Center Amsterdam, said in the statement.The company said Oligomannate will be available in China "very soon," and it is currently seeking approval to market it abroad, with plans to launch third-phase clinical trials in the US and Europe in early 2020.Alzheimer's disease, which starts with memory loss and escalates to severe brain damage, is believed to cause 60% to 70% of the cases of dementia reported worldwide, according to the World Health Organization. Dementia affects an estimated 50 million people worldwide, including 9.5 million people in mainland China, Hong Kong and Taiwan.Named after Alois Alzheimer, the neuropathologist who discovered the disease in 1906, it has so far confounded researchers and pharmaceutical companies.In October, US pharmaceutical giant Biogen said it would pursue Food and Drug Administration (FDA) approval for an experimental treatment called aducanumab, after announcing in March it was canceling a large clinical trial for the drug.Johnson & Johnson, Merck, Pfizer and Eli Lilly have all previously abandoned projects to develop a drug for Alzheimer's after unsatisfactory clinical data.
Related video above: Researchers Developing Most Powerful MRI Hope to Help Detect Illnesses Like Alzheimers Disease Sooner
Authorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.
The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's, according to a statement from China's drug safety agency. The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn should any safety issues arise.
In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.
In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed suppresses certain bacteria contained in the gut which can cause neural degeneration and inflammation of the brain, leading to Alzheimer's.
This mechanism was confirmed during a clinical trial carried out by Green Valley, a Shanghai-based pharmaceutical company that will be bringing the new drug to market.
Conducted on 818 patients, the trial found that Oligomannate -- which is derived from brown algae -- can statistically improve cognitive function among people with Alzheimer's in as little as four weeks, according to a statement from Green Valley.
"These results advance our understanding of the mechanisms that play a role in Alzheimer's disease and imply that the gut microbiome is a valid target for the development of therapies," neurologist Philip Scheltens, who advises Green Valley and heads the Alzheimer Center Amsterdam, said in the statement.
The company said Oligomannate will be available in China "very soon," and it is currently seeking approval to market it abroad, with plans to launch third-phase clinical trials in the US and Europe in early 2020.
Alzheimer's disease, which starts with memory loss and escalates to severe brain damage, is believed to cause 60% to 70% of the cases of dementia reported worldwide, according to the World Health Organization. Dementia affects an estimated 50 million people worldwide, including 9.5 million people in mainland China, Hong Kong and Taiwan.
Named after Alois Alzheimer, the neuropathologist who discovered the disease in 1906, it has so far confounded researchers and pharmaceutical companies.
In October, US pharmaceutical giant Biogen said it would pursue Food and Drug Administration (FDA) approval for an experimental treatment called aducanumab, after announcing in March it was canceling a large clinical trial for the drug.
Johnson & Johnson, Merck, Pfizer and Eli Lilly have all previously abandoned projects to develop a drug for Alzheimer's after unsatisfactory clinical data.
More:
China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years - WAPT Jackson
How did a neuroscientist ameliorate seizures in her daughter #39;s Lennox-Gastaut syndrome?
In this video segment, Neurology Today #39;s Editor-in-Chief Steven P. Ringel, MD, talks with Tracy Dixon-Salazar, PhD, associate research director at Citizens U...
By: Neurology Today
Go here to read the rest:
How did a neuroscientist ameliorate seizures in her daughter's Lennox-Gastaut syndrome? - Video
How Does an Implanted Device Help Patients Predict and Detect Seizures?
Editorial board member Jacqueline A. French, MD, selected a Lancet Neurology paper for Neurology Today #39;s annual "Best Advances of 2013" issue. The study obse...
By: Neurology Today
Continued here:
How Does an Implanted Device Help Patients Predict and Detect Seizures? - Video
Warren Chiropractic presents Quantum Neurology R Rehabilitation for Multiple Sclerosis Nicole
A young lady with many strange neurological symptoms of sciatica pain, burning pain, lack of sensation with numbness and tingling, lack of feeling in certain...
By: Kathy Warren
Originally posted here:
Warren Chiropractic presents Quantum Neurology R Rehabilitation for Multiple Sclerosis Nicole - Video
My Neurology Diagr--er, Minecraft Presentation
By: Dunkan Bulk
More here:
My Neurology Diagr--er, Minecraft Presentation - Video
Warren Chiropractic presents Quantum Neurology R Rehabilitation for Arthritic Joints Teresa
Patient describes the debilitating pain from arthritis in the knees and other joints. Quantum Neurology (R) Rehabilitation corrects pain dysfunction, along...
By: Kathy Warren
See the rest here:
Warren Chiropractic presents Quantum Neurology R Rehabilitation for Arthritic Joints Teresa - Video
Denver Migraine Doctor: How We Help Migraines Even If You #39;re On Prescription Medications
http://www.DenverMigraineHelp.com - Denver Migraine Doctor - Migraine Doctor Denver - If you suffer from migraine headaches, this video explains how we can h...
By: Denver Migraine - Denver Chiropractic Neurology - Integrated Health Systems Denver
Follow this link:
Denver Migraine Doctor: How We Help Migraines Even If You're On Prescription Medications - Video
Cosmo Care - Neurology 2014
By: Cosmo Care
Continue reading here:
Cosmo Care - Neurology 2014 - Video